Latest Intellectual Property News

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Aeeris Ltd reported a strong Q4 FY25 with a 13.3% increase in annual recurring revenue, driven by the full deployment of its proprietary AWARE system and strategic in-house service transitions.

Locate Technologies Limited reported a significant cash burn in its latest quarterly cash flow report, highlighting ongoing operational and investing outflows amid stable financing arrangements.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

EcoGraf Limited has advanced its vertically integrated battery anode materials business with a US$105 million financing mandate for its Epanko Graphite Mine and positive momentum in US and EU government support.

Holista Colltech reported steady customer receipts and a 38% surge in dietary supplement sales for 2QFY25, while progressing its high-value nano-collagen business and refreshing its leadership team.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Iondrive Limited advances its proprietary battery recycling technology with a pilot plant design, European consortium formation, and new e-waste initiatives, supported by significant grant funding.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

TALi Digital has acquired the You Can Do It! education program, boosting its social-emotional learning portfolio, while raising $0.8 million through a private placement to support growth initiatives.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.